
Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
XORTX Therapeutics Inc. (XRTX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1,79, with a market capitalisation of $3,76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,73 to $7,05. This page covers its latest market performance, valuation, price trends and company information.
$3,76M | |
$1,76 | |
$1 513,35 | |
$1,73 | |
$1,88 | |
854,00 | |
70,85K | |
-- | |
$7,05 | |
$1,73 | |
-- | |
-- |
XORTX Therapeutics Inc. (XRTX) is trading at $1,79 in pre-market trading as of 2026-09-16 10:21:00, down 5,05% ($0,09) from the previous close of $1,88
Pre-market trading shows how investors are pricing XRTX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, XORTX Therapeutics Inc. (XRTX) moved from $2,31 to $1,79, representing a decline of 22,73% ($0,53).
The stock traded between $1,75 and $2,45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 536,28 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1,1%
XRTX is currently trading at $1,79, placing it 1,1% of the way from its 52-week low of $1,73 to its 52-week high of $7,05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of XORTX Therapeutics Inc. (XRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.